Oral IIb/IIIa Antiplatelet Development Winding Down; Four Companies Out
Eight clinical development programs for oral glycoprotein IIb/IIIa receptor antagonists are being closed down in response to lack of compound efficacy.
Eight clinical development programs for oral glycoprotein IIb/IIIa receptor antagonists are being closed down in response to lack of compound efficacy.